Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
BICO Group AB (publ) (BICO.ST)
Gothenburg, SE
BICO Group AB (publ) is a global bio-convergence enterprise, extending its operations across North America, Europe, Asia, and other international markets. Its business is segmented into two primary divisions: Laboratory Solutions and Bioautomation. The Laboratory Solutions division equips researchers with advanced tools like 3D bioprinters, hybrid microscopes, and instruments for single-cell dispensing and liquid handling. It also supplies essential consumables such as bioinks, reagents, microscope lenses, and specialized software, alongside 3D reconstructed human tissues crucial for regulatory testing. Furthermore, this segment provides specialized services in 3D cell culture, tissue imaging, multiplex imaging, and digital pathology, primarily benefiting pharmaceutical and biotechnology firms. Conversely, the Bioautomation segment caters to industrial clients with precision dispensing and biosensor technologies, while also delivering diagnostic automation and sophisticated robotics solutions to the medical and diagnostics sectors. Beyond these segments, BICO Group's comprehensive portfolio includes solutions for tissue engineering, multi-omics, cell line development, and diagnostics, contributing to a robust industrial ecosystem. Its principal clientele spans the medical, pharmaceutical, and cosmetic industries. Originally established in 2016 as Cellink AB (publ), the company adopted its current name, BICO Group AB (publ), in August 2021. Its headquarters are located in Gothenburg, Sweden.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -7.60% | -10.31% | -2.85% | +1.84% | -11.48% | -12.00% | -49.49% | -70.14% | -95.17% | +30.20% | +30.20% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%-23.1% Q1'26: -15.1% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%-19,187.5% Q1'26: +44.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%-17.7% Q1'26: +12.8% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%-16.8% Q1'26: -31.6% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%-12.8% Q1'26: -26.8% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+0.0% ★ Q1'26: -2.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-43.12× Q1'26: -5.20× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 2 EPS Ana. |
Dec 2027 3 Rev. Ana. 2 EPS Ana. |
Dec 2028 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
176.79M
est: 175.00M (+1.0%)
|
1.26B
est: 1.22B (+3.0%)
|
2.24B
est: 2.28B (-1.8%)
|
2.01B
est: 2.42B (-17.0%)
|
1.95B
est: 2.00B (-2.7%)
|
1.50B
est: 1.54B (-2.9%)
|
1.57B
1.55B – 1.59B
+1.6% YoY
|
1.69B
1.67B – 1.71B
+7.8% YoY
|
1.84B
1.84B – 1.84B
+8.9% YoY
|
| EBITDA |
-39.50M
est: 14.90M (-365.2%)
|
31.80M
est: 103.94M (-69.4%)
|
322.30M
est: 194.12M (+66.0%)
|
442.80M
est: 303.30M (+46.0%)
|
505.30M
est: 250.43M (+101.8%)
|
-34.90M
est: 192.89M (-118.1%)
|
195.98M
193.63M – 199.12M
+1.6% YoY
|
211.34M
209.20M – 214.52M
+7.8% YoY
|
230.18M
230.18M – 230.18M
+8.9% YoY
|
| EBIT |
-66.09M
est: -38.91M (-69.9%)
|
-160.00M
est: -271.45M (+41.1%)
|
-618.30M
est: -506.97M (-22.0%)
|
-701.40M
est: -439.48M (-59.6%)
|
27.00M
est: -362.88M (+107.4%)
|
-252.10M
est: -279.50M (+9.8%)
|
-283.97M
-288.52M – -280.56M
-1.6% YoY
|
-306.22M
-310.83M – -303.12M
-7.8% YoY
|
-333.53M
-333.53M – -333.53M
-8.9% YoY
|
| Net Income |
-61.89M
est: -105.86M (+41.5%)
|
-229.20M
est: -230.45M (+0.5%)
|
-835.70M
est: 197.69M (-522.7%)
|
-1.17B
est: -1.50B (+21.7%)
|
-5.50M
est: -364.52M (+98.5%)
|
-1.09B
est: -1.56B (+30.2%)
|
-206.65M
-407.80M – -1.53M
+86.8% YoY
|
-112.00M
-363.21M – 137.37M
+45.8% YoY
|
-48.65M
-56.98M – -41.83M
+56.6% YoY
|
| SGA |
85.65M
est: 75.01M (+14.2%)
|
433.10M
est: 523.30M (-17.2%)
|
719.00M
est: 977.33M (-26.4%)
|
986.20M
est: 1.04B (-4.7%)
|
978.00M
est: 854.77M (+14.4%)
|
714.60M
est: 658.38M (+8.5%)
|
668.91M
660.88M – 679.63M
+1.6% YoY
|
721.32M
714.02M – 732.17M
+7.8% YoY
|
785.64M
785.64M – 785.64M
+8.9% YoY
|
| EPS |
-1.47
est: -1.50 (+2.0%)
|
-4.00
est: -3.27 (-22.5%)
|
-12.99
est: 2.80 (-564.5%)
|
-16.62
est: -21.23 (+21.7%)
|
-0.08
est: -5.15 (+98.4%)
|
-15.43
est: -22.05 (+30.0%)
|
-2.90
-5.78 – -0.02
+86.8% YoY
|
-1.60
-5.15 – 1.95
+44.8% YoY
|
-0.70
-0.81 – -0.59
+56.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-08 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-07 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-06 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-05 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-04 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-30 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-29 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P International Small Cap ETF GWX | 0.01% | 66.2K | 0.40% |
| 2 | Avantis International Small Cap Value ETF AVDV | 0.00% | 574.3K | 0.36% |
| 3 | Avantis International Small Cap Equity ETF AVDS | 0.00% | 7.7K | 0.30% |
| 4 | Avantis Global Small Cap Value UCITS ETF AVGS.L | 0.00% | 11.6K | 0.39% |
| 5 | State Street SPDR Portfolio Developed World ex-US ETF SPDW | 0.00% | 189.2K | 0.03% |
| 6 | State Street SPDR Portfolio Europe ETF SPEU | 0.00% | 2.5K | 0.07% |
| 7 | Avantis International Equity ETF AVDE | 0.00% | 25.0K | 0.23% |
| 8 | Dimensional - International Small Cap Value ETF DISV | 0.00% | 6.1K | 0.42% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Maria Forss | President & Chief Executive Officer | 8M | female |
| Andreas Joersjo | Advisor | — | — |
| Asa Hillsten | Senior Vice President & Head of Investor Relations | — | female |
| Catharina Nordlund | Global Head of Human Resources | — | female |
| Erica Bell | Senior Vice President & Chief People Officer | — | female |
| Ewa Linsater | Chief Financial Officer | — | female |
| Fraser McLeod | Managing Director of Biosero | — | male |
| Itedale Namro Redwan | Chief Scientific Officer - Bioprinting | — | female |
| Jacob Thordenberg | Executive Officer | — | male |
| Jesper Hagberg | Chief Operations & Digital Officer | — | male |
| Lars Risberg | General Counsel | — | male |
| Nicolas Gabriel-Robez | Chief Security Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BICO.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
